CD274 and acute myeloid leukemia: Moreover, PD-1 over-expression on lymphocytes as well as its two ligands PD-L1 and PD-L2 on CD34+ AML cells, may contribute to treatment resistance to azacytidine (137), providing the rationale to combine hypomethylating agents (HMA) and ICPIs in the treatment of AML (76, 140, 141).